Cerus Stock Forum

$Cerus (CERS.US)$ TD Cowen analyst Josh Jennings maintains $Cerus (CERS.US)$ with a buy rating, and maintains the target price at $5.

$Cerus (CERS.US)$
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
In Europe, the CE ...

Chatter increasing on this ticker, here are the levels to keep an eye on.
Larger Image: tradingview.com...
$Cerus (CERS.US)$  

$Cerus (CERS.US)$ Cerus Corp Awarded $248,591,407.65 Biomedical Advanced Research and Development Authority Contract From The Department Of Human Services For Health R&D Services; Health Care Services; Experimental Development
Benzinga· 6 mins ago

$Cerus (CERS.US)$ Earnings Flash (CERS) CERUS CORPORATION Reports Q2 Revenue $50.5M, Vs. Street Est of $42.5M
Cerus Outlook FY Revenue USD 175-178 Million

$Cerus (CERS.US)$ Director Shan Hua purchased 2,500 shares of common stock on May 13, 2024 at an average price of $1.9899 for a total value of $4,974.75.

$Cerus (CERS.US)$ Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

$Cerus (CERS.US)$ 🚀🚀🚀

$Cerus (CERS.US)$ Cerus Announces Positive Results For Phase 3 Trial Of Intercept Blood System